Neurogene, Inc. Common Stock (NGNE) is a publicly traded Healthcare sector company. As of August 11, 2026, NGNE trades at $34.53 with a market cap of $712.03M and a P/E ratio of -8.54. NGNE moved -6.05% today. Year to date, NGNE is +77.43%; over the trailing twelve months it is +72.24%. Its 52-week range spans $6.88 to $43.66. Analyst consensus is strong buy with an average price target of $80.71. Rallies surfaces NGNE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
9 analysts cover NGNE: 0 strong buy, 9 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $80.71.
| Metric | Value |
|---|---|
| Price | $34.53 |
| Market Cap | $712.03M |
| P/E Ratio | -8.54 |
| EPS | $-4.24 |
| Dividend Yield | 0.00% |
| 52-Week High | $43.66 |
| 52-Week Low | $6.88 |
| Volume | 15.94K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-90.35M |
| Gross Margin | 0.00% |
9 analysts cover NGNE: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $80.71.